FDA warned Omeza LLC over mold, insects and animal waste in drug manufacturing areas and unapproved nonprescription drugs.
What happened
FDA inspected Omeza LLC's drug manufacturing facility in Sarasota, Florida, from July 24-28, 2023. Investigators saw mold-like substance on an air conditioning unit sleeve directly above the manufacturing area, and live and dead insects plus animal waste in areas used to store bulk drug products and samples. FDA also reviewed product labels and the Omeza website and found Omeza Lidocaine Lavage and Omeza Skin Protectant marketed as unapproved new drugs outside applicable nonprescription monograph conditions.
What FDA found
The company did not keep buildings clean and free of pests; FDA saw mold-like material above the manufacturing area and live and dead insects plus animal waste in storage areas.
21 CFR 211.56(a)The company did not test each incoming component for identity and did not establish that suppliers' test results were reliable; FDA cited cod liver oil and lidocaine examples.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not follow a written stability program and used stability data from a different product to set expiration dates.
21 CFR 211.166(a)FDA says Omeza Lidocaine Lavage is an unapproved new drug because its labeling goes beyond the external analgesic monograph and omega-3s is not an allowed active ingredient.
FD&C Act section 505(a), 21 U.S.C. 355(a)FDA says Omeza Skin Protectant is an unapproved new drug because labeling for rashes and eczema is not permitted with cod liver oil as the active ingredient.
FD&C Act section 505(a), 21 U.S.C. 355(a)FDA says both products are misbranded because they are nonprescription drugs that do not meet section 505G requirements.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)
What FDA wants
FDA asks Omeza to respond in writing within 15 working days describing corrections and prevention, including reserve-sample testing, environmental monitoring and risk assessments, supplier qualification review, and a stability-program assessment. FDA also recommends engaging a qualified CGMP consultant.
Who should pay attention
- companies making or selling nonprescription skin or wound-care drugs
- brands that buy from contract manufacturers or rely on supplier certificates
- quality teams responsible for pest control, component testing and stability programs
This is a summary. Read the original letter on fda.gov.